Related Experiment Video
Updated: Jan 20, 2026

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
Published on: July 23, 2016
Clinical Management of Pharmacokinetic Drug Interactions with Direct Oral Anticoagulants (DOACs)
Megan C Herink1, Yan F Zhuo2, Craig D Williams2
1Department of Pharmacy Practice, OSU/OHSU College of Pharmacy, 2730 SW Moody Ave., CL5CP, Portland, OR, 97201, USA. herink@ohsu.edu.
Abstract:
Compared with warfarin, the direct-acting oral anticoagulants (DOAC) have fewer pharmacokinetic drug interactions. However, significant drug interactions do exist with documented changes in DOAC concentrations, which can exceed 100%. Unlike warfarin, DOACs have no validated surrogate test to monitor the intensity of anticoagulation. However, several analyses of major outcomes trials with DOACs have demonstrated that serum concentrations do affect both the thrombotic benefits and the hemorrhagic risks of these agents. This paper reviews the known significant pharmacokinetic interactions with DOACs and includes considerations for their use in the presence of interacting medications.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pharmacokinetics: Drug–Drug Interactions
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Direct-Acting Cholinergic Agonists: Pharmacokinetics
Esophageal Perforation-II: Clinical Manifestations and Management
Clinical Manifestations:

